CAJ | 학술논문

目的观察多西他赛联合奥沙利铂同步化、放疗治疗局部晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应.方法 72例Ⅲ期NSCLC患者采用抽签法分为2组:治疗组35例进行同期放化疗,化疗在放疗开始时同期进行,用药多西他赛75 mg/m2第1天静脉滴注;奥沙利铂130 mg/m2第2天静脉滴注.21 d为1个周期,共2个周期.放疗采用X线三维适形放疗,2 Gy/次,5 次/周,总剂量60～70 Gy/30～50次,6～7周内完成.对照组37例只行三维适形放疗,具体剂量、分割方式同治疗组.治疗完成后评价疗效和不良反应.结果治疗组总有效率80.0%,完全缓解率22.9%;对照组总有效率56.8%,完全缓解率10.8%,2组间总有效率差异有统计学意义(x2=5.77,P＜0.05).治疗组1、2年生存率分别为68.6%、42.9%,对照组分别为40.5%、18.9%.治疗组肿瘤进展时间平均为10.2个月,单纯放疗组为4.5个月(x2=6.34,P＜0.05).经对症治疗后均顺利完成,治疗过程无治疗相关死亡.结论多西他赛联合奥沙利铂同期放疗可以提高晚期非小细胞肺癌的近期疗效和远期生存率,是一种安全有效的综合治疗手段.
목적 관찰다서타새연합오사리박동보화、방료치료국부만기비소세포폐암(NSCLC)적림상료효화불량반응.방법 72례Ⅲ기NSCLC환자채용추첨법분위2조:치료조35례진행동기방화료,화료재방료개시시동기진행,용약다서타새75 mg/m2제1천정맥적주;오사리박130 mg/m2제2천정맥적주.21 d위1개주기,공2개주기.방료채용X선삼유괄형방료,2 Gy/차,5 차/주,총제량60～70 Gy/30～50차,6～7주내완성.대조조37례지행삼유괄형방료,구체제량、분할방식동치료조.치료완성후평개료효화불량반응.결과 치료조총유효솔80.0%,완전완해솔22.9%;대조조총유효솔56.8%,완전완해솔10.8%,2조간총유효솔차이유통계학의의(x2=5.77,P＜0.05).치료조1、2년생존솔분별위68.6%、42.9%,대조조분별위40.5%、18.9%.치료조종류진전시간평균위10.2개월,단순방료조위4.5개월(x2=6.34,P＜0.05).경대증치료후균순리완성,치료과정무치료상관사망.결론 다서타새연합오사리박동기방료가이제고만기비소세포폐암적근기료효화원기생존솔,시일충안전유효적종합치료수단.
Objective To observe the efficacy and side effects of docetaxel and oxaliplatin based chemotherapy and concurrent radiotherapy in local advanced non-small cell lung cancer(NSCLC). Methods Seventy-two patients with local advanced non-small cell lung cancer were divided into two groups randomly. Thirty-five cases in the treatment group received 2 cycles of docetaxel 75 mg/m2 on day 1 and oxaliplatin 130 mg/m2 on day 2 with 21 days for 1 cycle. And followed by three-dimensional conformal radiotherapy(3D-CRT)(2 Gy/f, 5 f/w, totally 60-70 Gy). Thirty-seven cases in the control group were treated by 3D-CRT only. The clinical response was assessed after treatment. Results Overall response rate, 1 and 2-year survival rates and average tumor progress time were higher in the concurrent chemoradiotherapy group( 80.0% ,68.6% ,42.9% and 10.2 months respectively) than those in the radiotherapy alone group (56. 8%, 40.5%, 18.9% and 4. 5 months respectively). Conclusions Docetaxel and oxaliplatin based chemotherapy and concurrent radiotherapy in local advanced non-small cell lung cancer can improve short term response rate, survival rates and average tumor progress time. The regiment is well tolerable and effective.